218 related articles for article (PubMed ID: 26668132)
41. Advances in knowledge of inhibitor formation in severe haemophilia A.
Cormier M; Batty P; Tarrant J; Lillicrap D
Br J Haematol; 2020 Apr; 189(1):39-53. PubMed ID: 32064603
[TBL] [Abstract][Full Text] [Related]
42. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.
Ettinger RA; James EA; Kwok WW; Thompson AR; Pratt KP
Blood; 2009 Aug; 114(7):1423-8. PubMed ID: 19549986
[TBL] [Abstract][Full Text] [Related]
43. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
44. The impact of von Willebrand factor on factor VIII memory immune responses.
Chen J; Schroeder JA; Luo X; Shi Q
Blood Adv; 2017 Aug; 1(19):1565-1574. PubMed ID: 28920105
[TBL] [Abstract][Full Text] [Related]
45. Inhibitory antibodies in hemophilia A.
Pratt KP
Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
[TBL] [Abstract][Full Text] [Related]
46. Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries.
Schmidt A; Brettschneider K; Kahle J; Orlowski A; Becker-Peters K; Stichel D; Schulze J; Braner M; Tampé R; Schwabe D; Königs C
Thromb Haemost; 2016 Jul; 116(1):32-41. PubMed ID: 27009573
[TBL] [Abstract][Full Text] [Related]
47. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
48. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.
Jing W; Chen J; Cai Y; Chen Y; Schroeder JA; Johnson BD; Cui W; Shi Q
Blood Adv; 2019 Oct; 3(20):3099-3110. PubMed ID: 31648333
[TBL] [Abstract][Full Text] [Related]
49. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
50. Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
Lacroix-Desmazes S; Pratt KP
Front Immunol; 2020; 11():639386. PubMed ID: 33569066
[No Abstract] [Full Text] [Related]
51. Anti-factor VIII antibodies: a 2005 update.
Lavigne-Lissalde G; Schved JF; Granier C; Villard S
Thromb Haemost; 2005 Oct; 94(4):760-9. PubMed ID: 16270627
[TBL] [Abstract][Full Text] [Related]
52. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
[TBL] [Abstract][Full Text] [Related]
53. A cellular viewpoint of anti-FVIII immune response in hemophilia A.
André S; Meslier Y; Dimitrov JD; Repessé Y; Kaveri SV; Lacroix-Desmazes S; Dasgupta S
Clin Rev Allergy Immunol; 2009 Oct; 37(2):105-13. PubMed ID: 19165635
[TBL] [Abstract][Full Text] [Related]
54. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
55. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
57. Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.
Lai JD; Cartier D; Hartholt RB; Swystun LL; van Velzen AS; den Haan JMM; Hough C; Voorberg J; Lillicrap D
J Thromb Haemost; 2018 Mar; 16(3):533-545. PubMed ID: 29285874
[TBL] [Abstract][Full Text] [Related]
58. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
59. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
[TBL] [Abstract][Full Text] [Related]
60. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates.
Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R
Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
